BVE Cannabis & Psilocybin Life Sciences Venture Capital by info@bve.vc

This is Arlene.

This is Arlene on drugs.

Investment Thesis

Government Adoption

U.S. Food & Drug Administration (FDA)

Approved Epidiolex in 2018, the ﬁrst plant derived CBD drug approved by the agency. Sold in 2021 for $7.2 billion.

U.S. Drug Enforcement Administration (DEA)

Began expediting controlled substances research licenses in 2018 and has proposed a massive increase in research grade production of cannabis and psilocybin of 6300% in 2022.

National Institutes of Health (NIH)

Issued ﬁrst federal research funding in 50 years to Johns Hopkins University in 2021. Members of the Senate issued a letter to NIH requesting expanded research of psychedelics.

Defense Advanced Research Projects Agency (DARPA)

In 2022, provided $26.9 million in funding to the University of North Carolina’s Medical School to fund psychedelic research as a part of the Focused Pharma mental health program.

U.S. Department of Agriculture (USDA)

The 2018 Farm Bill differentiated hemp from cannabis, legalized regulated hemp production and directed the USDA to develop the regulatory framework for hemp farming in the US.

INNOVATION

Addressing Needs in Large Patient Populations

Therapeutic Indication U.S. Patient Population U.S. Healthcare Costs = $2.7 Trillion Parkinson’s Disease 1.1 million $52 billion Fibromyalgia 6 - 12 million $18 billion Treatment Resistant Depression 4.4 million $326 billion Post-traumatic Stress Disorder 15 million $232 billion Pain 50 million $635 billion Alzheimer’s Disease 16 million $244 billion Mental Health 52.9 million $225 billion Sexual Wellness F: 43% & M: 31% $11 billion Eating Disorders 28 million $64.7 billion Cancer Treatment 1.7 million/year $240 billion Traumatic Brain Injury 5.3 million $48.3 billion Sleep Aids 9 million $118 billion Use Disorders (Alcohol, Nicotine, Opioids) 59.5 million $454 billion Epilepsy 3- 4 million $8.6 billion © 2022 Bonaventure Equity, LLC. All rights reserved 8

Key Investment Drivers

LACK OF INSTITUTIONAL CAPITAL RECEPTIVE REGULATORY AGENCIES HEALTHCARE DISRUPTION INNOVATION SOLVING FOR LARGE UNMET MEDICAL NEEDS INCREASE IN ENTREPRENEURSHIP IMMINENT WAVE OF M&A TRANSACTIONS © 2022 Bonaventure Equity, LLC. All rights reserved 9

Track Record - Fund I is up 2.5x unrealized gains in first year - Eleven investments to date 3. 4. 5. Differentiated Venture Capital 1. We Invest in Scientific Innovation - Pioneering investment strategy - Hold the space to ourselves 2. Focused Venture Capital - Seed Series A Venture Capital - Significant funding gap, lack of institutional capital in the space Purpose Built Platform - Shoulder to shoulder with management teams - Team of entrepreneurial, life sciences, biotech, regulatory, and scientific research experts We Are the Authority - Proprietary off market dealflow - Preferential terms © 2022 Bonaventure Equity, LLC. All rights reserved 10

Portfolio & Pipeline

Genetics AgTech company focused on plant diagnostics and development; currently in the market with genetics testing products.

Leading chemical engineering ﬁrm developing scalable high quality synthetic cannabinoids. cGMP certiﬁed processing lab servicing CBD and isolate markets developing proprietary formulations for FDA application.

Clinical stage biopharmaceutical company focused on developing and commercializing psilocybin and other innovative psychedelic therapies for the treatment of mental illness in patients with cancer and other life-threatening diseases.

CBN biotech discovery and commercialization company, at break-even raising capital to scale proprietary processing technologies, toxicity studies and eﬃcacy research.

Pre-IPO commercializing a portfolio of patented cannabinoid formulations for treatment of chronic and neuropathic pain.

Engineering focused ﬁrm, designer and manufacturer of medical testing device, currently proﬁtable and expanding beyond the consumer market with a "razor razor blade" technology for supply chain and direct to consumer applications.

Seasoned Life Sciences team partnering with Darpa Funded psychedelic researchers to commercialize novel neurological therapies.

MINIMUM

Fund proﬁts (5) years following the date of initial close

Ten (10) years after the date of the ﬁnal close; two optional 1-year extensions at General Partner’s discretion, at cost

FUND SIZE: MANAGEMENT FEE: CARRIED INTEREST: FIRST CLOSE: FUND LIFE: CO-INVESTMENT RIGHTS: INVESTMENT MANAGER: Bonaventure Equity, LLC Up To $30,000,000 2.5% of Capital Commitments during the Investment Period 1.5% of invested and unreturned Capital Commitments after the Investment Period Terms

COMMITMENT SIZE: INVESTMENT PERIOD: $250,000

80/20 split between Limited Partners and General Partner December 2021 Five

Offered

Three Simple Takeaways

1.Psychedelic drugs are efﬁcacious (they work).

They are safe and well tolerated.

They are on the cusp of completely disrupting healthcare.

The Markets Are Huge: Therapeutic Indication U.S. Patient Population U.S. Healthcare Costs = $2.7 Trillion Parkinson’s Disease 1.1 million $52 billion Fibromyalgia 6 - 12 million $18 billion Treatment Resistant Depression 4.4 million $326 billion Post-traumatic Stress Disorder 15 million $232 billion Pain 50 million $635 billion Alzheimer’s Disease 16 million $244 billion Mental Health 52.9 million $225 billion Sexual Wellness F: 43% & M: 31% $11 billion Eating Disorders 28 million $64.7 billion Cancer Treatment 1.7 million/year $240 billion Traumatic Brain Injury 5.3 million $48.3 billion Sleep Aids 9 million $118 billion Use Disorders (Alcohol, Nicotine, Opioids) 59.5 million $454 billion Epilepsy 3- 4 million $8.6 billion © 2022 Bonaventure Equity, LLC. All rights reserved 16

Government Agency Receptivity

U.S. Food & Drug Administration (FDA)

Approved Epidiolex in 2018, the ﬁrst plant derived CBD drug approved by the agency. Sold in 2021 for $7.2 billion.

U.S. Drug Enforcement Administration (DEA)

Began expediting controlled substances research licenses in 2018 and has proposed a massive increase in research grade production of cannabis and psilocybin of 6300% in 2022.

National Institutes of Health (NIH)

Issued ﬁrst federal research funding in 50 years to Johns Hopkins University in 2021. Members of the Senate issued a letter to NIH requesting expanded research of psychedelics.

Defense Advanced Research Projects Agency (DARPA)

In 2022, provided $26.9 million in funding to the University of North Carolina’s Medical School to fund psychedelic research as a part of the Focused Pharma mental health program.

U.S. Department of Agriculture (USDA)

The 2018 Farm Bill differentiated hemp from cannabis, legalized regulated hemp production and directed the USDA to develop the regulatory framework for hemp farming in the US.

Once off limits, government agencies are receptive to cannabis and psychedelics as viable options for treating signiﬁcant unmet medical needs.

Types of Psychedelic Substances Psychotropic Drug 5-HT2a 5-HT2b 5-HT2c KOR Family Target Indication(s) DMT ++ +++ +++ - Tryptamine TRD, Alzheimer’s, Pain, Addiction Mescaline - +++ - - Other Inﬂammation MDMA - +++ - - Phenethylamine Autism, PTSD Psilocin ++ +++ ++ - Tryptamine Depression, PTSD, Fragile X Ibogaine + - - ++ Iboga Alkaloid Addition LSD +++ +++ +++ - Ergoline Anxiety, Addiction, Migraine Ketamine - - - + Other Depression, Parkinson’s Legend: +++ = very high // ++ = high // + = moderate // – = low to not detectable Source: ARK Investment Management LLC, 2022. © 2022 Bonaventure Equity, LLC. All rights reserved 18

DEA Drug Classiﬁcation Schedule Drug Examples DEA Description Schedule I LSD, MDMA,, Psilocybin, Mescaline, Cannabis, Ecstasy, Peyote, Heroin High abuse potential and no approved medical use Schedule II Cocaine, Demerol, OxyContin, Fentanyl, Adderall, Ritalin, Methamphetamine, Morphine High abuse potential Schedule III Ketamine, Hydrocodone, Anabolic Steroids, Testosterone Moderate to low abuse potential Schedule IV Xanax, Valium, Ambien, Tramadol Low abuse potential Schedule V Codeine-based cough medicines Very low abuse potential Source: United States Drug Enforcement Administration © 2022 Bonaventure Equity, LLC. All rights reserved 19

Well Known Academic Researchers

Psychedelic Research Increasing

Source: ARK Investment Management LLC, 2022; Data derived from Web of Science

Evidence of Activity: Psilocybin

Evidence of Activity

Robin Carhart-Harris et. Al, Royal Publishing Society: 06 December 2014https://doi.org/10.1098/rsif.2014.0873

Evidence of Activity

Robin Carhart-Harris et. Al, Imperial College of London

Target Indication Frequency

Source: ARK Investment Management LLC, 2022

JourneyLife

PLEASEDONOTCIRCULATE

Sciences SUMMER2022

Major Pain

Categories NociceptivePain Caused by damage to body tissue, often through an external injury. May feel like sharp, aching, or throbbing. Commonexamplesinclude: ◦ Sprains ◦ Bonefractures ◦ Burns ◦ Inflammation NeuropathicPain NociplasticPain Caused by damage or disease directly affecting the nervous system, usually leading to burning, coldness, pins-and-needles sensations,numbness,anditching. Commonexamplesinclude ◦ Nervetrauma ◦ Carpaltunnelsyndrome ◦ Widespreadnervedamage ◦ Certaintypesofcancerpain Newly Identified Caused by misfiring within the CNS which can lead to widespread multifocal pain that is more intense thanwouldbeexpected. Commonexamplesinclude ◦ Fibromyalgia ◦ Phantomlimbpain ◦ Lowerbackpain ◦ Irritablebowelsyndrome(IBS) © 2022 Bonaventure Equity, LLC. All rights reserved 27

Nociplastic Treatment

Pain: Few

Alternatives PhantomLimbPain Over 1 million diagnosed with phantomlimbpainintheUS. Existing treatment methods (all ineffective)include: ◦ Generalpainmeds ◦ Mirrortherapy ◦ Acupuncture ChronicLowerBackPain ComplexRegionalPain Syndrome Effects over 16 million people in the US. Common treatments include: ◦ Physical therapy ◦ Mindfulness & meditation ◦ Injection-based treatments ◦ Alternatives: acupuncture, massage, biofeedback laser, ENS ◦ Pharmacologic treatments: analgesics, anti-inﬂammatory drugs, muscle relaxants, opioids CRPSresultsfrommisﬁringofpain signals within the brain after an injury, surgery, stroke or heart attack. There are approximately 100,000 peoplediagnosedwithCRPSinUS. Noeffectivetreatmentsavailable. © 2022 Bonaventure Equity, LLC. All rights reserved 28

Global Market Opportunity: $15.9 billion

Academic Collaborations

Josh Woolley, MD, Ph.D. of California, San Francisco

-AssociateProfessor,Departmentof

Boris D,

Initial

-AssistantProfessorofAnesthesiology,

Initial

Fadel Zeidan Ph.D. of California,

-AssociateProfessorofAnesthesiology

Adam

University

study: Phase 2a study in Chronic, Treatment Resistant Lower Back Pain

PsychiatryandBehavioralSciences -Director,TranslationalPsychedelic Research(TrPR)Program

Heifets, MD, Ph.D. Stanford University

PerioperativeandPainMedicine

Woolley,

University

San Diego

-Director,UCSanDiegoCenterfor Mindfulness

Halberstadt, Ph.D. University of California, San Diego -AssociateProfessorofPsychiatry